Order Article Reprints

Nardin C, Hennemann A, Diallo K, Funck-Brentano E, Puzenat E, Heidelberger V, Jeudy G, Samimi M, Lesage C, Boussemart L, et al. Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC). Cancers. 2023; 15(14):3564. https://doi.org/10.3390/cancers15143564

Nardin, Charlée, Aymeric Hennemann, Kadiatou Diallo, Elisa Funck-Brentano, Eve Puzenat, Valentine Heidelberger, Géraldine Jeudy, Mahtab Samimi, Candice Lesage, Lise Boussemart, and et al. 2023. "Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)" Cancers 15, no. 14: 3564. https://doi.org/10.3390/cancers15143564

Nardin, C., Hennemann, A., Diallo, K., Funck-Brentano, E., Puzenat, E., Heidelberger, V., Jeudy, G., Samimi, M., Lesage, C., Boussemart, L., Peuvrel, L., Rouanet, J., Brunet-Possenti, F., Gerard, E., Seris, A., Jouary, T., Saint-Jean, M., Puyraveau, M., Saiag, P., & Aubin, F. (2023). Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC). Cancers, 15(14), 3564. https://doi.org/10.3390/cancers15143564